Spain, May 8 -- Spain based NOVARTIS FARMACEUTICA, S.A. has secured contract from Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad for Immunosuppressive agents - Supply of medicines for human use containing the following active ingredients: alpelisib, asciminib, basiliximab, brolucizumab, canakinumab, capmatinib, ceritinib, dabrafenib, midostaurin, ofatumumba, ribociclib, ruxolitinib, secukinumab, siponimod and trametinib, destined for Valencian public health centers. The value of the contract is not disclosed.
Published by HT Digital Content Services with permission from Pivotal Sources....